Tempest Therapeutics (TPST) Set to Announce Earnings on Wednesday

Tempest Therapeutics (NASDAQ:TPST) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Tempest Therapeutics to announce earnings of ($0.32) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Tempest Therapeutics (NASDAQ:TPST) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). On average, analysts expect Tempest Therapeutics to post ($0.83) EPS for the current fiscal year and ($0.90) EPS for the next fiscal year.

Tempest Therapeutics Price Performance

Shares of Tempest Therapeutics stock opened at $0.51 on Wednesday. Tempest Therapeutics has a 52-week low of $0.50 and a 52-week high of $11.12. The business’s 50 day simple moving average is $0.85 and its 200 day simple moving average is $1.55.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TPST. Wall Street Zen upgraded Tempest Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Friday, October 9th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment.

Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.